These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 3761571

  • 1. Cardiovascular effects of budralazine in the dog.
    Chiba S, Saegusa K, Furukawa Y, Ogiwara Y.
    Jpn Heart J; 1986 May; 27(3):403-11. PubMed ID: 3761571
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology of budralazine, a new antihypertensive drug.
    Akashi A, Chiba T, Suzuki I, Hashimoto H.
    Arch Int Pharmacodyn Ther; 1978 Sep; 235(1):134-46. PubMed ID: 736687
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular responses to a newly developed cardiotonic agent, ZSY-39 [4-methyl-5-(4-pyridinyl)-thiazole-2-carboxyamide] in dog cross-circulated atrial and ventricular preparations.
    Chiba S, Furukawa Y, Saegusa K, Ogiwara Y, Takeda M.
    Jpn Heart J; 1987 Mar; 28(2):253-60. PubMed ID: 3599412
    [Abstract] [Full Text] [Related]

  • 4. Positive chronotropic and inotropic effects of angiotensin II in the dog heart.
    Kobayashi M, Furukawa Y, Chiba S.
    Eur J Pharmacol; 1978 Jul 01; 50(1):17-25. PubMed ID: 679973
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological analyses of hydralazine-induced cardiac action in intact dogs and isolated, blood-perfused canine atria.
    Saegusa K, Furukawa Y, Chiba S.
    J Cardiovasc Pharmacol; 1986 Jul 01; 8(3):614-20. PubMed ID: 2425181
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular effects of methylflavonolamine hydrochloride (SIPI-549) in cross-circulated canine atrial and ventricular preparations.
    Chiba S, Akabane K, Furukawa Y, Karasawa Y.
    Jpn Heart J; 1989 Jul 01; 30(4):511-21. PubMed ID: 2572710
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological analysis of cardiac effects of a central cholinergic agent, WEB 1881-FU, in isolated canine heart preparations.
    Chiba S, Karasawa Y, Akahane K, Ren LM.
    Jpn Heart J; 1990 Mar 01; 31(2):217-25. PubMed ID: 2355458
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the vasodilator action of antihypertensive drug budralazine.
    Chiba T, Hirohashi M, Suzuki I, Tanaka S, Watanabe K, Akashi A.
    Arzneimittelforschung; 1983 Mar 01; 33(1):112-6. PubMed ID: 6299307
    [Abstract] [Full Text] [Related]

  • 9. Bradycardic effects of AQ-A 39 (falipamil) in situ and in isolated, blood-perfused dog hearts. Comparison with alinidine and verapamil.
    Ogiwara Y, Furukawa Y, Akahane K, Haniuda M, Chiba S.
    Jpn Heart J; 1988 Nov 01; 29(6):849-61. PubMed ID: 3241338
    [Abstract] [Full Text] [Related]

  • 10. Central sympathoinhibitory action of a direct-acting vasodilator, budralazine, in anesthetized rats.
    Yoshioka M, Yahagi H, Minami M, Saito H.
    Jpn J Pharmacol; 1987 Jun 01; 44(2):187-96. PubMed ID: 3656776
    [Abstract] [Full Text] [Related]

  • 11. Positive inotropic and negative chronotropic effects of OPC-8490, a newly developed cardiotonic, in isolated, blood-perfused canine heart preparations.
    Furukawa Y, Akahane K, Haniuda M, Chiba S.
    Jpn Heart J; 1989 May 01; 30(3):387-98. PubMed ID: 2552190
    [Abstract] [Full Text] [Related]

  • 12. Pre- and postsynaptic alpha-adrenergic effects of the antihypertensive drug budralazine.
    Shibamura S, Chiba T, Suzuki I, Akashi A.
    Arzneimittelforschung; 1981 May 01; 31(7):1076-9. PubMed ID: 6268123
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of dibutyryl cyclic AMP in the intact dog heart and the isolated cross-perfused right atrium.
    Furukawa Y, Ogiwara Y, Saegusa K, Takeda M, Chiba S.
    Jpn Heart J; 1988 Jul 01; 29(4):465-73. PubMed ID: 2846907
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular effects of a new phenoxyalkylamine derivative, 2-isopropyl-5-[3-(2-methoxyphenoxy)propylamino]-2-(3,4,5-trimethoxy phenyl) valeronitrile fumarate (HV-525), in cross-circulated dog atrial preparations.
    Chiba S, Ogiwara Y, Furukawa Y, Saegusa K.
    Jpn Heart J; 1987 Mar 01; 28(2):261-72. PubMed ID: 3599413
    [Abstract] [Full Text] [Related]

  • 15. The anti-tachycardic mechanism of a direct-acting vasodilator, budralazine, in rats.
    Yoshioka M, Minami M, Saito H.
    Clin Exp Hypertens A; 1991 Mar 01; 13(5):1107-14. PubMed ID: 1773498
    [Abstract] [Full Text] [Related]

  • 16. Antihypertensive and general pharmacological properties of budralazine.
    Chiba T, Shibamura S, Tanaka M, Yamasaki T, Hashimoto H, Kurebayashi Y, Kasai Y, Ryokawa Y, Tamura K, Hirohashi M, Akashi A.
    Arzneimittelforschung; 1981 Mar 01; 31(7):1080-7. PubMed ID: 7023495
    [Abstract] [Full Text] [Related]

  • 17. Different effectiveness of glucagon on the pacemaker activity and contractility in intact dog hearts and in isolated perfused right atria.
    Furukawa Y, Saegusa K, Ogiwara Y, Chiba S.
    Jpn Heart J; 1986 Mar 01; 27(2):215-22. PubMed ID: 3723799
    [Abstract] [Full Text] [Related]

  • 18. Bradycardic effect of alinidine on in situ and on isolated, blood-perfused heart preparations of dogs.
    Ogiwara Y, Furukawa Y, Saegusa K, Takeda M, Chiba S.
    Arch Int Pharmacodyn Ther; 1988 Mar 01; 291():41-54. PubMed ID: 2835022
    [Abstract] [Full Text] [Related]

  • 19. Effect of secretin on pacemaker activity and contractility in the isolated blood-perfused atrium of the dog.
    Chiba S.
    Clin Exp Pharmacol Physiol; 1976 Mar 01; 3(2):167-72. PubMed ID: 975612
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.